Guizhou Bailing Group Pharmaceutical Co.Ltd(002424) it was announced on December 27 that the company and its wholly-owned subsidiary Zhengxin pharmaceutical recently received the notice of approval for supplementary application for drug clinical trial approved and issued by the State Food and drug administration, and agreed that the company’s “Shuangyang houbitong Granule” would be used for acute pharyngitis and pharyngitis in children aged 6 and over after modifying and improving the clinical trial scheme Clinical trial of sore throat caused by acute tonsillitis (exogenous wind heat syndrome).
“Shuangyang houbitong Granule” is a listed product of Zhengxin pharmaceutical, a wholly-owned subsidiary of the company. In the “list of OTC drug enterprises and products in 2021” published by China over the counter drug association, “Shuangyang houbitong Granule” ranks sixth in the comprehensive statistics of “Chinese patent medicine · throat”. It is proposed to change the scope of applicable population for children with sore throat caused by acute pharyngitis and acute tonsillitis (exogenous wind heat syndrome). In the future, the company will carry out phase II and III clinical trials according to the requirements of new drugs according to the changes of listed traditional Chinese medicine and requirements for application materials.
The company said that this application to expand the scope of application of “Shuangyang houbitong Granule” will further enhance the market competitiveness of this variety and have a positive impact on the improvement of the company’s profitability.
(Shanghai Securities News · China Securities Network)
